The Key Intermediates of Apixaban — Make Synthesis of Apixaban More Efficiently
Apixaban is an oral, direct factor Xa inhibitor that inhibits both free and clot-bound factor Xa, and has been approved for clinical use in several thromboembolic disorders with good results.
The synthesis of Apixaban is complex with low yield. Therefore, selecting key intermediates as raw materials can synthesize Apixaban more efficiently[1-3]:
• Reduce reaction steps and time;
• Reduce reaction costs;
• Avoid using large amounts of PCl5 which is instability and difficult to work-up;
• Avoid excessive use of morpholine as it will inevitably produce by-products, which limits industrialization.
ChemExpress is capable of providing intermediates of Apixaban with mature technology, stable supply and production capacity of tons. Purchase request: contact us at (+86) 021-58950125 or send email to [email protected]
Explore more about Apixaban>
About ChemExpress
➤ We focus on providing RSMs, intermediates, APIs/HPAPIs, especially with high difficulty and high-performance process development, scale-up, and registration
➤ Products of raw materials and intermediate (100kg to tons) required for preclinical/clinical stage and commercialization
➤ Anti-tumor, Anti-virus, Diabetes, Cardio cerebral vascular Disease treatment and other fields
➤ 120+ types of raw materials and intermediate products, of which 100+ products are commercialized
➤ Special Reactions: Grignard reaction, Oxidation reaction, Chlorination reaction, Hydrogenation reaction, High-pressure hydrogenation, Ultralow temperature reaction, Diazotization reaction, Nitration reaction, Chlorination reaction
If you want to know more about our products and capabilities, please click the website of ChemExpress: https://www.chemexpress.com/category/intermediate-for-api-production-1
Reference:
[1] Clin Pharmacokinet. 2019, 58, 1265-1279.
[2] Bristol-Myers Squibb, Pfizer EEIG. EU summary of product characteristics: Eliquis (apixaban tablets). 2018.
[3] Bristol-Myers Squibb Company PI. Eliquis (apixaban) prescribing information. 2018.
[4] CN101967145